First-in-Human Case Study: Multipotent Adult Progenitor Cells for Immunomodulation After Liver Transplantation

URN to cite this document:: urn:nbn:de:bvb:355-epub-512289
DOI to cite this document:: 10.5283/epub.51228

Soeder, Yorick ; Loss, Martin ; Johnson, Christian L. ; Hutchinson, James A.

; Haarer, Jan ; Ahrens, Norbert

; Offner, Robert

; Deans, Robert J. ; Van Bokkelen, Gil ; Geissler, Edward K.

; Schlitt, Hans J.

; Dahlke, Marc H.

Preview

PDF - Published Version
(1MB)

Date of publication of this fulltext: 21 Dec 2021 06:32

Alternative links to fulltext:DOI Publisher

Details

Preview

Export bibliographical data

Abstract

Mesenchymal stem cells and multipotent adult progenitor cells (MAPCs) have been proposed as novel therapeutics for solid organ transplant recipients with the aim of reducing exposure to pharmacological immunosuppression and its side effects. In the present study, we describe the clinical course of the first patient of the phase I, dose-escalation safety and feasibility study, MiSOT-I (Mesenchymal ...